ライフサイエンスコーパス: bone density

1 decreased bone volume fraction and alveolar bone density.

2 e pathophysiology of nephrolithiasis and low bone density.

3 tures suggesting a positive role of GPR40 on bone density.

4 s result in van Buchem disease with elevated bone density.

5 able, display chondrodysplasia and decreased bone density.

6 nosine A(1) receptor blockade or deletion on bone density.

7 rovide a comprehensive synopsis of pediatric bone density.

8 ts of weight lifting, including increases in bone density.

9 ion in the growth plate and lower trabecular bone density.

10 were adjusted for age, sex, knee injury, and bone density.

11 , decreasing bone resorption, and increasing bone density.

12 treatment regimen, and weight, could predict bone density.

13 isease activity were associated with reduced bone density.

14 neral apposition and an increase in alveolar bone density.

15 s to the risk of hip fracture independent of bone density.

16 bolic acidosis may have a negative effect on bone density.

17 0 dollars, depending on age and femoral neck bone density.

18 sessed for alveolar crestal height (ACH) and bone density.

19 ometric analysis including new bone area and bone density.

20 tropic effects on body fat, lipid levels and bone density.

21 ting the beneficial effects of L. reuteri on bone density.

22 in mice with skeletal dwarfism and decreased bone density.

23 ting the beneficial effects of L. reuteri on bone density.

24 steoclast numbers and, additionally, loss of bone density.

25 screening method for assessment of skeletal bone density.

26 d strains of mice regulate bone strength and bone density.

27 could benefit from intervention to increase bone density.

28 g medical conditions associated with reduced bone density.

29 illus reuteri in healthy male mice increases bone density.

30 SD decrease in radius trabecular volumetric bone density.

31 resorption of bone that results in increased bone density.

32 nitoring of serum calcium concentrations and bone density.

33 kinky hair, thin-pitted enamel and increased bone density.

34 ous activity and phosphaturia with decreased bone density.

35 bitor of angiogenesis and known regulator of bone density.

36 lated as a percentage relative to the native bone density.

37 molecular explanation for abnormal increased bone density.

38 cognitive and behavioral impairments and low bone density.

39 or source of dietary flavonoids, with higher bone density.

40 stronger as were those between VAT and lower bone densities.

41 rea, 35.8 +/- 3.6 versus 30.1 +/- 2.2 mm(2); bone density, 31.8% +/- 1.6% versus 35.6% +/- 2.5%; and

42 omal dominant syndrome characterized by high bone density, a wide and deep mandible, and torus palati

43 r vertical bitewings were taken for alveolar bone density (ABD) and alveolar bone height (ABH) measur

44 vertical bite-wings were taken for alveolar bone density (ABD) and alveolar bone height (ABH) measur

45 s of vitamin A (retinol), on post-natal peak bone density acquisition and skeletal remodeling are com

46 (mean +/- SD) 4.9 +/- 3.0% and 2.8 +/- 3.2% bone density after 1 year versus placebo, which lost (me

47 the use of bisphosphonates for retention of bone density after joint replacement.

48 f 945 women were previously unaware of their bone density, although, for 344 (36.4%), osteoporosis wa

49 Fractures to estimate risk of fracture from bone density and age in postmenopausal women.

50 in a gradual loss of effect, as measured by bone density and biochemical markers of bone remodeling.

51 The corresponding bone density and bone-implant contact registrations aver

52 the strongest associations between systemic bone density and CAL among women without subgingival cal

53 circulating SHBG affects the body impedance, bone density and cholesterol levels, among others.

54 investigating associations between systemic bone density and clinical attachment loss (CAL) of the s

55 /-) mice does not normalize mass, length, or bone density and content in fgf21(-/-)ksr2(-/-) mice.

56 ny postmenopausal women are unaware of their bone density and could benefit from screening.

57 eiving ADT, once-weekly alendronate improves bone density and decreases turnover.

58 association of magnesium and potassium with bone density and demonstrate that further investigation

59 e in Scd-1 expression, and 10.6% increase in bone density and entirely lacked the alopecia phenotype

60 etic bone disease characterized by increased bone density and fragility.

61 ave advantages, including the maintenance of bone density and high concentrations of growth factors.

62 In addition, bone density and histology revealed no differences betwe

63 Osteoporosis is associated with decreased bone density and increased bone fragility, but how this

64 g genetic component characterized by reduced bone density and increased fracture risk.

65 low vitamin K intake has been related to low bone density and increased risk of osteoporotic fracture

66 ence was associated with increased vertebral bone density and increased whole-body bone dimensions an

67 ades, they have also been suffering from low bone density and its clinical manifestations, fractures

68 s raise the possibility that the increase in bone density and loss of cartilage that are characterist

69 e Aldh1a1 as a novel determinant of cortical bone density and marrow adiposity in the skeleton in viv

70 in hormone levels during menopause decrease bone density and may worsen oral health, favoring the gr

71 Systemic bone density and oral infection independently influenced

72 ns (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in me

73 t population includes men and women with low bone density and osteoporosis.

74 Other outcomes, including bone density and other serum lipid levels, did not chang

75 y; cause gastrointestinal problems; decrease bone density and production of blood cells; and cause fe

76 actions in other tissues, acting to promote bone density and protect against cardiovascular disease,

77 is, physicians should assess their patients' bone density and provide preventive and therapeutic meas

78 plete, higher-protein meal plan on change in bone density and quality as compared with weight stabili

79 ned to this meal plan would maintain similar bone density and quality to weight-stable controls, desp

80 higher-protein meal plan maintained similar bone density and quality to weight-stable controls.

81 to quantitative imaging techniques measuring bone density and quality, imaging needs to be used to di

82 idence suggests that it can increase femoral bone density and reduce fracture risk.

83 Nox4(-/-) mice displayed higher bone density and reduced numbers and markers of osteocla

84 ether peripheral serotonin has any effect on bone density and remodeling.We therefore decided to inve

85 The TAF-based regimen had less effect on bone density and renal function than the other regimens.

86 genes enriched for genes known to influence bone density and strength (maximum odds ratio (OR) = 58,

87 macologic inhibitors of this enzyme improved bone density and strength in two rodent models of osteop

88 rts that deficits in trabecular and cortical bone density and structure independently contribute to f

89 ture risk and identify strategies to improve bone density and structure.

90 AC5 KO mice are protected from reduced bone density and susceptibility to fractures of aging.

91 Low bone density and the occurrence of vertebral fractures i

92 ular connectivity density, higher trabecular bone density and thicker structures, something that coul

93 to determine whether regional variations in bone density and trabecular architecture in relation to

94 derive the most benefit from measurements of bone density and treatments for bone diseases.

95 Differences in bone density and trunk lean body mass may account for so

96 Our objective was to examine changes in bone density and turnover with sustained, discontinued,

97 Antiretrovirals (ARVs) affect bone density and turnover, but their effect on risk of f

98 m binding protein D28k than normal mice, and bone density and volume increased in KO/TG compared with

99 man traits (e.g., height, cognitive ability, bone density) and disease risks (e.g., breast cancer, di

100 Muscle density, bone density, and background noise were measured.

101 for viability, fertility, growth, appetite, bone density, and fat deposition and not likely to be a

102 ects of dietary changes on osteoporosis, low bone density, and frequent falls are unestablished.

103 for the associations among prior fractures, bone density, and incident fractures; and published stud

104 veins, COL6A1 on corneal resistance, MEPE on bone density, and IQGAP2 and GMPR on blood cell traits.

105 s with relatively higher local medial tibial bone density, and lateral bone marrow lesions occur in k

106 neck was twice that in patients with normal bone density, and the difference was statistically signi

107 uded terms for osteoporosis, osteopenia, low bone density, and the drugs listed in the key questions.

108 ffect growth, cellular and humoral immunity, bone density, and wound healing.

109 It has been suggested that changes in bone density are not surrogates for reduction in fractur

110 ts in whom both hypercalciuria and decreased bone density are present.

111 ing normal basal bone osteoclast numbers and bone density, are resistant to physiological and patholo

112 ent instruments are modest predictors of low bone density (area under the curve, 0.13 to 0.87; 14 ins

113 h, the areas with the highest and the lowest bone density areas were all reduced.

114 Cetaceans utilize low bone density as a buoyancy control mechanism, but the un

115 Using densitometry to monitor changes in bone density as a measure of therapeutic efficacy has be

116 model, the mice treated GNPs-ALD had higher bone density as compared to other OVX mice groups.

117 QCT) was performed to measure the volumetric bone density as the most reliable parameter in vertebral

118 Condensation increased interfacial bone density, as measured by a significant change in bon

119 L3 and L4 vertebral mineral bone density, assessed by dual-energy x-ray absorption,

120 le no differences were found in radiographic bone density assessments.

121 ic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with o

122 echanical stimulus resulted in lower average bone density at convergence.

123 phy (microCT) analysis revealed an increased bone density at the bone-to-implant interface in the Osx

124 ed via total cross-sectional muscle area and bone density at the L3 vertebral level, compared with a

125 gressive declines in cortical and trabecular bone density at the peripheral skeleton.

126 Peri-implant bone density averaged 72.2% +/- 2.1% for coronal-load ve

127 G1 showed less bone density (BD) compared to G2.

128 percentage of defect fill (DF), newly formed bone density (BD), and new cementum formation (NCF) were

129 ion early in life has little effect on adult bone density because the juvenile bone is largely replac

130 ntom measurements were obtained to correlate bone densities between MRI sequences and CT.

131 an account for the different effect of LT on bone density between adult and pediatric populations in

132 We measured bone density (BMD), calciotropic hormones and bone turno

133 neral density (BMD) and estimated volumetric bone density (bone mineral apparent density [BMAD]).

134 is similar, HSL(-/-) mice maintain a higher bone density (bone volume/total volume 6.1%) with age th

135 to quantify fracture risk by measurement of bone density, bone quality, and risk factor algorithms.

136 cific foods or beverages and their effect on bone density, broadening understanding of eating pattern

137 loss has no clinically significant effect on bone density but slows bone turnover.

138 diopathic short stature (ISS) had no loss of bone density but were noted to have more vertebral abnor

139 with significant changes in measurements of bone density, but more studies of high doses and of ther

140 The associations between bone density, CAL, and subgingival calculus require furt

141 relationship between serum testosterone and bone density change were detected.

142 r percentage of trabecular bone and a higher bone density compared to controls (P < or =0.05) without

143 C/EBPalpha(+/-) mice exhibit an increase in bone density compared with C/EBPalpha(+/+) controls.

144 There was no measurable increase in bone density compared with that in unaffected individual

145 , we demonstrate low trabecular and cortical bone density contributing to lower volumetric bone miner

146 We measured trabecular bone densities, cortical bone densities, VAT areas, and

147 eased skeletal size, muscle mass, trabecular bone density, cortical bone geometry, and strength.

148 JRA patients had decreased tibia trabecular bone density, cortical bone size and strength, and muscl

149 ; total, cortical, and trabecular volumetric bone density; cortical area and thickness; and trabecula

150 en and women with baseline data was used for bone density cross-sectional analyses and combined with

151 PGE2 secreted by osteoblasts increases when bone density decreases as demonstrated in osteoporotic a

152 shed tumor-mediated osteolysis, and lessened bone density decrement in mice injected with breast canc

153 CRHR1 polymorphisms may impact the risk of bone density deficits in patients treated with corticost

154 cup daily) was associated with a 2%-4% lower bone density, depending on site (P < 0.001), but the odd

155 including impairments of growth velocity and bone density), diagnostic and therapeutic interventions,

156 an tissue mass to account for differences in bone density did not significantly alter the results.

157 n a small but significant improvement in hip bone density, did not significantly reduce hip fracture,

158 resulted in similar but not exactly the same bone density distribution at convergence.

159 ferent boundary conditions were applied, the bone density distributions at convergence were very diff

160 Bone densities (dual x-ray absorptiometry [DXA]) were no

161 Raloxifene maintains bone density (estrogen-like effect) in postmenopausal os

162 In 2013 patients with serial bone density examinations, total hip BMD increased trans

163 The low trabecular bone density found in hemophilia is attributed to signif

164 ssigned at year 2 to continue had additional bone density gains at the spine (mean, 2.3% +/- 0.7) and

165 P-2-treated sites showed better radiographic bone density, greater defect fill, and significantly mor

166 Decreased bone density has been increasingly associated with hyper

167 Women with low bone density have approximately a 40% to 50% reduction i

168 els and implications for overweight and poor bone density; high prevalence of obstructive sleep apnea

169 arms and whole body, lower pulse rate, lower bone density, higher odds of hip replacement, lower odds

170 linkage disequilibrium, were associated with bone density in a sex-specific manner.

171 graphy analysis of adult femurs showed lower bone density in A2BAR KO mice as compared with WT.

172 ic conditions, thus implicating FGF23 in low bone density in cetaceans.

173 pore size >1 mm demonstrated higher mineral bone density in comparison with meshes with pore size <1

174 roducts may be more effective in maintaining bone density in equol-producing individuals.

175 cession, and significant changes in alveolar bone density in focal areas.

176 ng adulthood, assessing stimulant effects on bone density in growing children is of critical importan

177 ected controls, but with the highest loss of bone density in infected gp91(phox) KO mice.

178 al model parameters on the computed apparent bone density in mandible under normal chewing and biting

179 mature fusion of the cranial sutures and low bone density in newborn FGFR3(G380R) mice.

180 diet does not produce loss of hip and spine bone density in older adults and may improve bone qualit

181 idence supports that several medications for bone density in osteoporotic range and/or preexisting hi

182 We conclude by reviewing the loss of bone density in patients with AD, paralleling the increa

183 on with minimal fibrous tissue and increased bone density in rabbit radial defect models.

184 Statin use did not improve fracture risk or bone density in the Women's Health Initiative Observatio

185 Reduced bone density in this population is multifactorial and re

186 Bone density in this range was termed "osteopenia" by a

187 letal quality and strength despite preserved bone density in type 2 diabetes, as well as the effects

188 es the expression of bone markers, increases bone density in vivo, and is used clinically in the mana

189 ial for stimulated osteoclast activation and bone density in vivo.

190 While L. reuteri treatment increased bone density in wild type, no significant increases were

191 To optimise treatment of low bone density in women with epilepsy, studies investigati

192 ulating markers of bone turnover and reduced bone density in women.

193 ast lineage would affect bone resorption and bone density in young adult mice.

194 d long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, ca

195 Ablation of COUP-TFII in mice led to higher bone density, increased muscle mass, and suppression of

196 ctured limbs, C57BL/6 mice had a decrease in bone density, increased subchondral bone thickness, and

197 or nuclear factor-kappa B ligand (RANKL) and bone density index (BDI) were determined stereologically

198 Low bone density is a growing concern in aging men with hemo

199 While peak bone density is similar, HSL(-/-) mice maintain a higher

200 that the effect of habitual tea drinking on bone density is small and does not significantly alter t

201 ion of FGF23, a gene associated with reduced bone density, is greatly increased in the cetacean liver

202 Bone density levels did not statistically differ between

203 also significantly associated with alveolar bone density loss (p < 0.0001) and alveolar bone height

204 have been investigated in the prevention of bone density loss and skeletal morbidity.

205 e negative role of hemophilic arthropathy in bone density loss.

206 Loci associated with bone density/mass in both human and mouse were previousl

207 received osteoporosis treatment, final mean bone density (mean, 8.2 years after first scan) was aver

208 one density tests measured at various sites, bone density measured at the femoral neck by dual-energy

209 ip, posterior-anterior spine, and total-body bone density measured by using dual-energy x-ray absorpt

210 Subsequent bone density measurement identified osteoporosis in one

211 a for the diagnosis of osteoporosis based on bone density measurements have become apparent.

212 Although results of the bone density measurements were not significantly differe

213 ing such osteoporosis-related factors as low bone density, moderate and severe prevalent vertebral fr

214 Recommendation 4: ACP recommends against bone density monitoring during the 5-year pharmacologic

215 inistration of the two agents would increase bone density more than the use of either one alone.

216 osteoporosis (n = 30) and those with normal bone density (n = 29).

217 Recipients with normal bone density (n=24) were enrolled as controls.

218 one defect extension (RBDE); 2) newly formed bone density (NFBD); 3) total callus area (TCA); 4) oste

219 orse oral bone loss, in general, but neither bone density nor oral infection was significantly associ

220 ancer drug, keoxifene, was found to maintain bone density of rats (estrogenic action) while simultane

221 e of 0.25 mg/d of 17beta-estradiol increased bone density of the hip, spine, and total body, and redu

222 d classify compression fractures and measure bone density of thoracic and lumbar vertebral bodies on

223 periodontal ligament thickness, and alveolar bone density on the pressure side in IM-T1D were similar

224 tive rate, as well as to calculate vertebral bone density, on CT images.

225 inflammation, there were no improvements in bone density or bone mechanical properties; however, iri

226 Whether sensory nerve can sense bone density or metabolic activity to control bone homeo

227 approximately 15 years for women with normal bone density or mild osteopenia, 5 years for women with

228 We observed no effect, however, on either bone density or muscle regeneration in mice in which sig

229 prevent fractures in men and women with low bone density or osteoporosis.

230 eased odds of 1- and 2-year loss of alveolar bone density (OR = 1.98; P = 0.0001) in the placebo grou

231 studies, results of the WHI, and trials with bone density outcomes.

232 erapy (E/HRT) has beneficial effects on oral bone density over 3 years and that calcium and vitamin D

233 height (P <0.01), increased ridge width and bone density (P <0.01), enhanced 7-day prostaglandin E2

234 Extra-arterial pathology included low bone density (P<0.001); early onset degenerative spine d

235 tion of an Ezh2 inhibitor modestly increases bone density parameters of adult mice.

236 Deficits in spine bone density persisted after correcting for small bone s

237 mutations and its relationship to increased bone density phenotypes.

238 ate FRAX scores using data from the Manitoba Bone Density Program database of all women and men 40 ye

239 ors examined cross-sectional associations of bone density-related factors with blood lead levels amon

240 lations between VAT, muscle attenuation, and bone densities remained significant at -0.250, -0.119, a

241 ed phenotypes of this animal and the reduced bone density reported here parallel those of Cushing syn

242 /- 4.0% and 0.7 +/- 4.7%, in spine and femur bone density, respectively (p < or = 0.001 for the spine

243 ulatory mechanisms and cause higher or lower bone density, respectively.

244 and increased separation; the lower cortical bone density results from thinner cortices, whereas cort

245 tenuation as well as trabecular and cortical bone densities revealed negative correlations with BMI,

246 Bone density scans (dual-energy x-ray absorptiometry [DE

247 Bone density scores did not influence likelihood of PTx

248 Hemogram, lipids, and bone density should be periodically assessed in treated

249 ntakes, as well as circulating magnesium, on bone density status and fracture risk in an adult popula

250 dition, Ocy-PPARgamma(-/-) mice exhibit more bone density, structure, and strength by uncoupling bone

251 positron emission tomography (35.9%-53.6%), bone density studies (6.3%-20.0%), echocardiograms (5.0%

252 Bone density study performed 6 months earlier was normal

253 The Weight Loss, Protein and Bone Density Study was conducted from 2008 to 2011 in 32

254 In the MRL/MpJ mice, no differences in bone density, subchondral bone thickness, or histologic

255 , several studies of soy supplementation and bone density suggest that soy products may be more effec

256 ative association between BMI and muscle and bone densities, suggesting fat infiltration into these t

257 knees with relatively higher lateral tibial bone density, supporting the hypothesis that local BMD r

258 About half of postmenopausal women have a bone density T score at the femoral neck between -1.0 an

259 oups were similar in age, sex, CF mutations, bone density T scores, renal function, and body mass ind

260 role of risk factor assessment and different bone density techniques, frequency of screening, and ide

261 ave attempted to restrict the candidates for bone density testing.

262 t-term risk for fracture can be estimated by bone density tests and risk factors, and that fracture r

263 Among different bone density tests measured at various sites, bone densi

264 the effectiveness of risk factor assessment, bone density tests, or treatment were included.

265 and dolutegravir group had fewer changes in bone density than the two other treatment groups.

266 ion was associated with a small reduction in bone density that did not translate into an increased ri

267 these two fates may be key to the decreased bone density that occurs with aging.

268 n who were 46 to 85 years of age and had low bone density to receive alendronate (10 mg daily; 28 men

269 ypoglycemia, as well as reduction of mineral bone density, trabecular bone content, and subcutaneous

270 A model including cortical volumetric bone density, trabecular number, and trabecular thicknes

271 RT6-KO) mice display loss of muscle, fat and bone density, typical characteristics of cachexia.

272 MD monitoring and management, posttransplant bone density typically remains stable or improves with m

273 nges in serum biochemical values, trabecular bone density using micro-computed tomography, bone histo

274 measured trabecular bone densities, cortical bone densities, VAT areas, and subcutaneous adipose tiss

275 Hip bone density was 1.06 percent higher in the calcium plus

276 Bone density was assessed by dual energy x-ray absorptio

277 The increased bone density was associated with an increased bone forma

278 Bone turnover was lower, and bone density was higher, in obese people.

279 Bone density was lower in males (P = .001), in nonblack

280 In a subcohort (n = 5,022), bone density was measured and osteoporosis determined (n

281 Bone density was measured at the hip.

282 lth Initiative Observational Study, systemic bone density was measured at the spine, hip, forearm, an

283 Bone density was measured at three WHI centers.

284 Systemic bone density was measured by dual-energy x-ray absorptio

285 Bone density was measured by dual-energy X-ray absorptio

286 Bone density was measured using quantitative computed to

287 The interdental bone density was not affected in the absence of enamelin

288 Bone density was not decreased.

289 ression of circulating IGF-I; however, total bone density was significantly reduced.

290 Mean bone density was significantly superior in the test grou

291 n; median, 0.5 years after transplantation), bone density was slightly below average for age and sex

292 Femur bone density was unchanged in mice heterozygous for Drp1

293 lar bone loss (ABL) and lower interradicular bone density were detected in ligated molars in the CSI+

294 hormone binding globulin, gonadotropins, and bone density were measured and prednisone and CsA doses

295 alkaline phosphatase, 24-h urine calcium and bone density were performed.

296 We finally argue that bone density, which is currently the most routinely used

297 ifferentiation and favors the maintenance of bone density with aging.

298 Alendronate (ALN) increases alveolar bone density with systemic use and, has been found to in

299 The LRP5V171 mutation causes high bone density, with a thickened mandible and torus palati

300 can (mean, 2.7 years after first scan), mean bone density Z scores have increased (lumbar spine, -0.2